Published in Viruses on December 15, 2015
Open Babel: An open chemical toolbox. J Cheminform (2011) 11.12
Virtual screening of chemical libraries. Nature (2004) 4.84
Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol (2000) 4.83
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science (2003) 3.92
The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A (2003) 3.02
SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem (2011) 2.74
Structure-based virtual screening: an overview. Drug Discov Today (2002) 2.70
Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol (2004) 2.65
Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol (2006) 2.44
Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J Infect Dis (2005) 2.43
Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field. J Chem Theory Comput (2010) 2.22
Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem (2002) 2.10
Croup is associated with the novel coronavirus NL63. PLoS Med (2005) 2.03
Molecular dynamics simulations and drug discovery. BMC Biol (2011) 1.91
An outbreak of coronavirus OC43 respiratory infection in Normandy, France. Clin Infect Dis (2003) 1.88
Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol (2005) 1.73
Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis (2003) 1.58
Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol (2010) 1.54
Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc Natl Acad Sci U S A (2003) 1.53
Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today (2010) 1.49
A machine learning approach to predicting protein-ligand binding affinity with applications to molecular docking. Bioinformatics (2010) 1.48
Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol (2007) 1.41
High-throughput docking as a source of novel drug leads. Curr Opin Chem Biol (2004) 1.30
Conservation of substrate specificities among coronavirus main proteases. J Gen Virol (2002) 1.29
Recognizing pitfalls in virtual screening: a critical review. J Chem Inf Model (2012) 1.27
Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem (2005) 1.27
Structure-based drug design: docking and scoring. Curr Protein Pept Sci (2007) 1.25
Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J Biol Chem (2009) 1.23
Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J Med Virol (2006) 1.23
Coronaviruses in the limelight. J Infect Dis (2005) 1.20
Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1. J Virol (2008) 1.18
Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J Med Chem (2005) 1.13
Drug design targeting the main protease, the Achilles' heel of coronaviruses. Curr Pharm Des (2006) 1.09
Novel human mPGES-1 inhibitors identified through structure-based virtual screening. Bioorg Med Chem (2011) 1.05
Characterization of human coronavirus etiology in Chinese adults with acute upper respiratory tract infection by real-time RT-PCR assays. PLoS One (2012) 1.04
Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease. J Infect Dis (2009) 1.03
Consensus docking: improving the reliability of docking in a virtual screening context. J Chem Inf Model (2013) 1.02
Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett (2007) 1.02
Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry (2007) 1.01
The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase. Biochem Biophys Res Commun (2005) 1.00
Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters. Bioorg Med Chem (2005) 1.00
Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. J Med Chem (2006) 0.99
Long-range cooperative interactions modulate dimerization in SARS 3CLpro. Biochemistry (2006) 0.98
Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations. J Infect Dis (2013) 0.95
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening. J Med Chem (2009) 0.95
Combination of ligand- and structure-based methods in virtual screening. Drug Discov Today Technol (2013) 0.92
Molecular docking and structure-based drug design strategies. Molecules (2015) 0.91
Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J Med Chem (2006) 0.90
Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design. Molecules (2014) 0.89
Structure-based and ligand-based virtual screening of novel methyltransferase inhibitors of the dengue virus. BMC Bioinformatics (2011) 0.89
Profiling of substrate specificities of 3C-like proteases from group 1, 2a, 2b, and 3 coronaviruses. PLoS One (2011) 0.88
Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. J Med Chem (2006) 0.87
Crystal structures reveal an induced-fit binding of a substrate-like Aza-peptide epoxide to SARS coronavirus main peptidase. J Mol Biol (2006) 0.86
Mechanism for controlling the monomer-dimer conversion of SARS coronavirus main protease. Acta Crystallogr D Biol Crystallogr (2013) 0.85
Mutation of Asn28 disrupts the dimerization and enzymatic activity of SARS 3CL(pro) . Biochemistry (2010) 0.85
Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. J Med Chem (2006) 0.84
Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors. J Med Chem (2011) 0.83
Insight into the activity of SARS main protease: Molecular dynamics study of dimeric and monomeric form of enzyme. Proteins (2007) 0.82
Epidemiological and clinical features of human coronavirus infections among different subsets of patients. Influenza Other Respir Viruses (2013) 0.82
The interaction between severe acute respiratory syndrome coronavirus 3C-like proteinase and a dimeric inhibitor by capillary electrophoresis. Anal Biochem (2005) 0.81
Metabolic pathway analysis and molecular docking analysis for identification of putative drug targets in Toxoplasma gondii: novel approach. Bioinformation (2012) 0.81
First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood. BMC Infect Dis (2013) 0.81
Ligand supported homology modeling and docking evaluation of CCR2: docked pose selection by consensus scoring. J Mol Model (2011) 0.80
Virtual screening of novel reversible inhibitors for marine alkaline protease MP. J Mol Graph Model (2013) 0.79
Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease. Bioorg Med Chem Lett (2010) 0.78
Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening. Bioinformation (2012) 0.78
A large scale virtual screen of DprE1. Comput Biol Chem (2013) 0.77
Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach. Mol Divers (2014) 0.76
Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: homology modelling and molecular dynamic studies. BMC Struct Biol (2015) 0.76